## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8282901/publications.pdf Version: 2024-02-01



Nid Hdifi

#	Article	lF	CITATIONS
1	Extrapulmonary manifestations of COVID-19. Nature Medicine, 2020, 26, 1017-1032.	15.2	2,300
2	COVID-19 and Cardiovascular Disease. Circulation, 2020, 141, 1648-1655.	1.6	1,398
3	A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. New England Journal of Medicine, 2019, 380, 1618-1627.	13.9	837
4	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation, 2020, 20, 1800-1808.	2.6	683
5	A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. New England Journal of Medicine, 2017, 376, 440-450.	13.9	618
6	Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. New England Journal of Medicine, 2018, 378, 1386-1395.	13.9	601
7	The Variety of Cardiovascular Presentations of COVID-19. Circulation, 2020, 141, 1930-1936.	1.6	465
8	Hemodynamics of MechanicalÂCirculatoryÂSupport. Journal of the American College of Cardiology, 2015, 66, 2663-2674.	1.2	416
9	Development of a Novel Echocardiography Ramp Test for Speed Optimization and Diagnosis of Device Thrombosis in Continuous-Flow Left Ventricular Assist Devices. Journal of the American College of Cardiology, 2012, 60, 1764-1775.	1.2	322
10	PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. Journal of Heart and Lung Transplantation, 2017, 36, 1-12.	0.3	229
11	Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months. Circulation, 2017, 135, 2003-2012.	1.6	217
12	HVAD: The ENDURANCE SupplementalÂTrial. JACC: Heart Failure, 2018, 6, 792-802.	1.9	185
13	Hemodynamic Ramp Tests in Patients WithÂLeft Ventricular Assist Devices. JACC: Heart Failure, 2016, 4, 208-217.	1.9	177
14	Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1165.	3.0	170
15	Outcome of unplanned right ventricular assist device support for severe right heart failure after implantable left ventricular assist device insertion. Journal of Heart and Lung Transplantation, 2014, 33, 141-148.	0.3	163
16	An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. Journal of Heart and Lung Transplantation, 2017, 36, 1137-1153.	0.3	142
17	Reverse remodelling and myocardial recovery in heart failure. Nature Reviews Cardiology, 2018, 15, 83-96.	6.1	131
18	Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. Circulation, 2016, 134, 141-152.	1.6	127

#	Article	IF	CITATIONS
19	Mechanical Unloading in Heart Failure. Journal of the American College of Cardiology, 2018, 72, 569-580.	1.2	127
20	Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. Journal of Heart and Lung Transplantation, 2012, 31, 1-8.	0.3	124
21	Value of Hemodynamic Monitoring in Patients With Cardiogenic Shock Undergoing Mechanical Circulatory Support. Circulation, 2020, 141, 1184-1197.	1.6	123
22	Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. Journal of Heart and Lung Transplantation, 2016, 35, 528-536.	0.3	119
23	Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications. Intensive Care Medicine, 2022, 48, 1-15.	3.9	114
24	Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. Circulation, 2019, 139, 155-168.	1.6	113
25	The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. Journal of Heart and Lung Transplantation, 2017, 36, 50-58.	0.3	110
26	Bridge-to-Decision Therapy With a Continuous-Flow External Ventricular Assist Device in Refractory Cardiogenic Shock of Various Causes. Circulation: Heart Failure, 2014, 7, 799-806.	1.6	96
27	Primary results of longâ€term outcomes in the <scp>MOMENTUM</scp> 3 pivotal trial and continued access protocol study phase: a study of 2200 <scp>HeartMate</scp> 3 left ventricular assist device implants. European Journal of Heart Failure, 2021, 23, 1392-1400.	2.9	96
28	Approach to Acute Cardiovascular Complications in COVID-19 Infection. Circulation: Heart Failure, 2020, 13, e007220.	1.6	94
29	Left Ventricular Assist Devices for LifelongÂSupport. Journal of the American College of Cardiology, 2017, 69, 2845-2861.	1.2	91
30	Serial Echocardiography Using Tissue Doppler and Speckle Tracking Imaging to Monitor Right Ventricular Failure Before and After Left Ventricular Assist Device Surgery. JACC: Heart Failure, 2013, 1, 216-222.	1.9	90
31	Identification and Management of Pump Thrombus in the HeartWare Left Ventricular Assist Device System. JACC: Heart Failure, 2015, 3, 849-856.	1.9	77
32	Indications for and Findings on Transthoracic Echocardiography in COVID-19. Journal of the American Society of Echocardiography, 2020, 33, 1278-1284.	1.2	74
33	Heart Transplantation in Human Immunodeficiency Virus–Positive Patients. Journal of Heart and Lung Transplantation, 2009, 28, 667-669.	0.3	73
34	Use of a percutaneous temporary circulatory support device as a bridge to decision during acute decompensation of advanced heart failure. Journal of Heart and Lung Transplantation, 2018, 37, 100-106.	0.3	72
35	Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibilityâ€related adverse events. European Journal of Heart Failure, 2019, 21, 655-662.	2.9	72
36	Optimal Hemodynamics During Left Ventricular Assist Device Support Are Associated With Reduced Readmission Rates. Circulation: Heart Failure, 2019, 12, e005094.	1.6	71

#	Article	IF	CITATIONS
37	Early post-operative ventricular arrhythmias in patients with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2015, 34, 1611-1616.	0.3	70
38	Left Ventricular Decompression During Speed Optimization Ramps in Patients Supported by Continuous-Flow Left Ventricular Assist Devices: Device-Specific Performance Characteristics and Impact on Diagnostic Algorithms. Journal of Cardiac Failure, 2015, 21, 785-791.	0.7	69
39	Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. Journal of Heart and Lung Transplantation, 2016, 35, 108-114.	0.3	65
40	Accurate Quantification Methods for Aortic Insufficiency Severity in Patients With LVAD. JACC: Cardiovascular Imaging, 2016, 9, 641-651.	2.3	64
41	3D Morphological Changes in LV and RV During LVAD Ramp Studies. JACC: Cardiovascular Imaging, 2018, 11, 159-169.	2.3	62
42	Impact of Hemodynamic Ramp Test-Guided HVAD Speed and Medication Adjustments on Clinical Outcomes. Circulation: Heart Failure, 2019, 12, e006067.	1.6	60
43	Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. European Journal of Heart Failure, 2011, 13, 195-199.	2.9	58
44	Clinical hemodynamic evaluation of patients implanted with a fully magnetically levitated left ventricular assist device (HeartMate 3). Journal of Heart and Lung Transplantation, 2017, 36, 28-35.	0.3	58
45	Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation. Circulation: Heart Failure, 2017, 10, .	1.6	57
46	Tumor necrosis factor- $\hat{l}_{\pm}$ levels and non-surgical bleeding in continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2018, 37, 107-115.	0.3	53
47	Impact of long term left ventricular assist device therapy on donor allocation in cardiac transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 188-195.	0.3	52
48	Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device. Circulation: Heart Failure, 2018, 11, e005082.	1.6	51
49	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. American Journal of Transplantation, 2020, 20, 3198-3205.	2.6	48
50	Aspirin and left ventricular assist devices: rationale and design for the international randomized, placeboâ€controlled, nonâ€inferiority ARIES HM3 trial. European Journal of Heart Failure, 2021, 23, 1226-1237.	2.9	47
51	Anti–Factor Xa and Activated Partial Thromboplastin Time Measurements forÂHeparin Monitoring in MechanicalÂCirculatory Support. JACC: Heart Failure, 2015, 3, 314-322.	1.9	45
52	Incidence and predictors of myocardial recovery on long-term left ventricular assist device support: Results from the United Network for Organ Sharing database. Journal of Heart and Lung Transplantation, 2015, 34, 1624-1629.	0.3	45
53	Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial. Journal of Heart and Lung Transplantation, 2020, 39, 529-537.	0.3	44
54	Advanced heart failure in patients infected with human immunodeficiency virus: Is there equal access to care?. Journal of Heart and Lung Transplantation, 2014, 33, 924-930.	0.3	43

#	Article	IF	CITATIONS
55	Outcome of cardiac transplantation in patients requiring prolonged continuous-flow left ventricular assist device support. Journal of Heart and Lung Transplantation, 2015, 34, 89-99.	0.3	43
56	Novel echocardiographic parameters of aortic insufficiency in continuous-flow left ventricular assist devices and clinical outcome. Journal of Heart and Lung Transplantation, 2016, 35, 976-985.	0.3	43
57	The Prognostic Value of Electrocardiogram at Presentation to Emergency Department in Patients With COVID-19. Mayo Clinic Proceedings, 2020, 95, 2099-2109.	1.4	43
58	The Hemodynamic Effects of Aortic Insufficiency in Patients Supported With Continuous-Flow Left Ventricular Assist Devices. Journal of Cardiac Failure, 2017, 23, 545-551.	0.7	41
59	Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009101.	1.6	39
60	Atrial Arrhythmias and Electroanatomical Remodeling in Patients With Left Ventricular Assist Devices. Journal of the American Heart Association, 2017, 6, .	1.6	37
61	Clinical implications of hemodynamic assessment during left ventricular assist device therapy. Journal of Cardiology, 2018, 71, 352-358.	0.8	37
62	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure. Circulation: Heart Failure, 2020, 13, e006731.	1.6	37
63	Reverse Remodeling With Left Ventricular Assist Devices. Circulation Research, 2021, 128, 1594-1612.	2.0	36
64	Admission Cardiac Diagnostic Testing with Electrocardiography and Troponin Measurement Prognosticates Increased 30â€Day Mortality in COVIDâ€19. Journal of the American Heart Association, 2021, 10, e018476.	1.6	35
65	The first-in-human experience with a minimally invasive, ambulatory, counterpulsation heart assist system for advanced congestive heart failure. Journal of Heart and Lung Transplantation, 2018, 37, 1-6.	0.3	34
66	Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study. Journal of Heart and Lung Transplantation, 2020, 39, 518-525.	0.3	34
67	Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score. Journal of Heart and Lung Transplantation, 2014, 33, 675-681.	0.3	33
68	Molecular Mechanism of the Association Between Atrial Fibrillation and Heart Failure Includes Energy Metabolic Dysregulation Due to Mitochondrial Dysfunction. Journal of Cardiac Failure, 2019, 25, 911-920.	0.7	33
69	Discordance Between Clinical Assessment and Invasive Hemodynamics in Patients With Advanced Heart Failure. Journal of Cardiac Failure, 2020, 26, 128-135.	0.7	33
70	Long-term outcome of patients on continuous-flow left ventricular assist device support. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1606-1614.	0.4	31
71	Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2014, 33, 1119-1125.	0.3	31
72	Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. Journal of Cardiac Failure, 2018, 24, 249-254.	0.7	31

#	Article	IF	CITATIONS
73	Mediastinal radiation and adverse outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 378-381.	0.3	30
74	Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery. Expert Review of Medical Devices, 2017, 14, 15-26.	1.4	30
75	Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. American Journal of Transplantation, 2020, 20, 3620-3630.	2.6	27
76	Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device. Circulation Journal, 2018, 82, 2931-2938.	0.7	26
77	Aortic root thrombosis in patients supported with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2018, 37, 1425-1432.	0.3	25
78	New Challenges in the Treatment of Patients With Left Ventricular Support: LVAD Thrombosis. Current Heart Failure Reports, 2016, 13, 302-309.	1.3	24
79	Cannula and Pump Positions Are Associated With Left Ventricular Unloading and Clinical Outcome in Patients With HeartWare Left Ventricular Assist Device. Journal of Cardiac Failure, 2018, 24, 159-166.	0.7	23
80	Remote Cardiac Monitoring in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 556.	3.0	22
81	Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System. JACC: Heart Failure, 2022, 10, 12-23.	1.9	21
82	Recovery With Temporary Mechanical Circulatory Support While Waitlisted for Heart Transplantation. Journal of the American College of Cardiology, 2022, 79, 900-913.	1.2	20
83	Decoupling Between Diastolic Pulmonary Arterial Pressure and Pulmonary Arterial Wedge Pressure at Incremental Left Ventricular Assist Device (LVAD) Speeds Is Associated With Worse Prognosis After LVAD Implantation. Journal of Cardiac Failure, 2018, 24, 575-582.	0.7	19
84	Left Atrial Appendage Occlusion With Left Ventricular Assist Device Decreases Thromboembolic Events. Annals of Thoracic Surgery, 2019, 107, 1181-1186.	0.7	19
85	Increasing heart transplant donor pool by liberalization of size matching. Journal of Heart and Lung Transplantation, 2019, 38, 1197-1205.	0.3	19
86	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. Journal of the American Heart Association, 2020, 9, e016760.	1.6	19
87	Peak exercise capacity is a poor indicator of functional capacity for patients supported by a continuous-flow left ventricular assist device. Journal of Heart and Lung Transplantation, 2014, 33, 213-215.	0.3	18
88	Changes in pulmonary artery pressure before and after left ventricular assist device implantation in patients utilizing remote haemodynamic monitoring. ESC Heart Failure, 2019, 6, 138-145.	1.4	18
89	Aortic Insufficiency During HeartMate 3 Left Ventricular Assist Device Support. Journal of Cardiac Failure, 2020, 26, 863-869.	0.7	18
90	Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007516.	1.6	17

#	Article	lF	CITATIONS
91	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. Circulation: Heart Failure, 2021, 14, e007564.	1.6	17
92	Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2016, 35, 1311-1320.	0.3	15
93	Screening for Outflow Cannula Malfunction of Left Ventricular Assist Devices (LVADs) With the Use of Doppler Echocardiography: New LVAD-Specific Reference Values for Contemporary Devices. Journal of Cardiac Failure, 2016, 22, 808-814.	0.7	15
94	Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clinical Transplantation, 2020, 34, e14028.	0.8	15
95	Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study. Journal of Heart and Lung Transplantation, 2018, 37, 25-32.	0.3	14
96	Echocardiographic Changes in Patients Implanted With a Fully Magnetically Levitated Left Ventricular Assist Device (Heartmate 3). Journal of Cardiac Failure, 2019, 25, 36-43.	0.7	14
97	Impact of worsening of aortic insufficiency during HeartMate 3 LVAD support. Artificial Organs, 2021, 45, 297-302.	1.0	14
98	Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis. Circulation: Heart Failure, 2021, 14, e007909.	1.6	14
99	Impact of UNOS allocation policy changes on utilization and outcomes of patients bridged to heart transplant with intraâ€aortic balloon pump. Clinical Transplantation, 2022, 36, e14533.	0.8	14
100	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. JCI Insight, 2022, 7, .	2.3	14
101	The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery. Current Heart Failure Reports, 2018, 15, 250-259.	1.3	13
102	Aortic Insufficiency and Hemocompatibility-related Adverse Events in Patients with Left Ventricular Assist Devices. Journal of Cardiac Failure, 2019, 25, 787-794.	0.7	13
103	The cardiac intensive care unit and the cardiac intensivist during the COVID-19 surge in New York City. American Heart Journal, 2020, 227, 74-81.	1.2	13
104	Longitudinal Trajectories of Hemodynamics Following Left Ventricular Assist Device Implantation. Journal of Cardiac Failure, 2020, 26, 383-390.	0.7	13
105	Effect of Concomitant Tricuspid Valve Surgery With Left Ventricular Assist Device Implantation. Annals of Thoracic Surgery, 2020, 110, 918-924.	0.7	13
106	Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?. Circulation: Heart Failure, 2021, 14, e007916.	1.6	13
107	Myocardial Recovery After LVADÂImplantation. Journal of the American College of Cardiology, 2017, 70, 355-357.	1.2	12
108	Consequences of Retained Defibrillator and Pacemaker Leads After Heart Transplantation—An Underrecognized Problem. Journal of Cardiac Failure, 2018, 24, 101-108.	0.7	12

#	Article	IF	CITATIONS
109	Clinical Outcomes and Quality of Life With an Ambulatory Counterpulsation Pump in Advanced Heart Failure Patients. Circulation: Heart Failure, 2020, 13, e006666.	1.6	12
110	The Role of Palliative Care in Withdrawal of Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock. Journal of Pain and Symptom Management, 2021, 61, 1139-1146.	0.6	12
111	A Power Tracking Algorithm for Early Detection of Centrifugal Flow Pump Thrombosis. ASAIO Journal, 2021, 67, 1018-1025.	0.9	12
112	Right Ventricular Pressure–Volume Analysis During Left Ventricular Assist Device Speed Optimization Studies: Insights Into Interventricular Interactions and Right Ventricular Failure. Journal of Cardiac Failure, 2021, 27, 991-1001.	0.7	12
113	Development of De Novo Aortic Insufficiency in Patients With HeartMate 3. Annals of Thoracic Surgery, 2022, 114, 450-456.	0.7	12
114	Predictors of Hemodynamic Improvement and Stabilization Following Intraaortic Balloon Pump Implantation in Patients With Advanced Heart Failure. Journal of Invasive Cardiology, 2018, 30, 56-61.	0.4	12
115	Center Variability in Patient Outcomes Following HeartMate 3 Implantation: An Analysis of the MOMENTUM 3 Trial. Journal of Cardiac Failure, 2022, 28, 1158-1168.	0.7	12
116	Evolution in MechanicalÂCirculatoryÂSupport. Journal of the American College of Cardiology, 2015, 66, 2590-2593.	1.2	11
117	Left Ventricular Assist Device Deactivation via Percutaneous Closure of the Outflow Graft. Journal of Cardiac Failure, 2016, 22, 653-655.	0.7	11
118	Aortic Pulsatility Index: A Novel Hemodynamic Variable for Evaluation of Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 1045-1052.	0.7	11
119	Mechanical circulatory support devices: methods to optimize hemodynamics during use. Expert Review of Medical Devices, 2017, 14, 343-353.	1.4	10
120	Echocardiographic Predictors of Hemodynamics in Patients Supported With Left Ventricular Assist Devices. Journal of Cardiac Failure, 2018, 24, 561-567.	0.7	10
121	Left Ventricular Volume Reduction and Reshaping as a Treatment Option for Heart Failure. Structural Heart, 2020, 4, 264-283.	0.2	10
122	Deep Y-Descent in Right Atrial Waveforms Following Left Ventricular Assist Device Implantation. Journal of Cardiac Failure, 2020, 26, 360-367.	0.7	10
123	Adrenergic Activation, Fuel Substrate Availability, and Insulin Resistance in Patients With Congestive Heart Failure. JACC: Heart Failure, 2013, 1, 331-337.	1.9	9
124	Peripheral venous congestion causes time―and doseâ€dependent release of endothelinâ€1 in humans. Physiological Reports, 2017, 5, e13118.	0.7	9
125	Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. Journal of Heart and Lung Transplantation, 2019, 38, 997-999.	0.3	9
126	Improvement in Biventricular Cardiac Function After Ambulatory Counterpulsation. Journal of Cardiac Failure, 2019, 25, 20-26.	0.7	9

#	Article	IF	CITATIONS
127	Association Between "Unacceptable Condition―Expressed in Palliative Care Consultation Before Left Ventricular Assist Device Implantation and Care Received at the End of Life. Journal of Pain and Symptom Management, 2020, 60, 976-983.e1.	0.6	9
128	Association of preoperative infections, nasal <scp><i>Staphylococcus aureus</i></scp> colonization and gut microbiota with left ventricular assist device outcomes. European Journal of Heart Failure, 2021, 23, 1404-1415.	2.9	9
129	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.3	9
130	Machine Learning-Based Prediction of Myocardial Recovery in Patients With Left Ventricular Assist Device Support. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008711.	1.6	9
131	Continuous Monitoring of Blood Pressure Using a Wrist-Worn Cuffless Device. American Journal of Hypertension, 2022, 35, 407-413.	1.0	9
132	Increased Rate of Pump Thrombosis and Cardioembolic Events Following Ventricular Tachycardia Ablation in Patients Supported With Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, 1127-1136.	0.9	8
133	Transcatheter Aortic Valve Replacement in Left Ventricular Assist Device Patients with Aortic Regurgitation. Structural Heart, 2020, 4, 107-112.	0.2	8
134	HVAD Flow Waveform Estimates Left Ventricular Filling Pressure. Journal of Cardiac Failure, 2020, 26, 342-348.	0.7	8
135	Influence of Atrial Fibrillation on Functional Tricuspid Regurgitation in Patients With HeartMate 3. Journal of the American Heart Association, 2021, 10, e018334.	1.6	8
136	Bleeding and Thrombotic Events During Extracorporeal Membrane Oxygenation for Postcardiotomy Shock. Annals of Thoracic Surgery, 2022, 113, 131-137.	0.7	8
137	Obesity is not a contraindication to veno-arterial extracorporeal life support. European Journal of Cardio-thoracic Surgery, 2021, 60, 831-838.	0.6	8
138	Changes in waitlist and posttransplant outcomes in patients with adult congenital heart disease after the new heart transplant allocation system. Clinical Transplantation, 2021, 35, e14458.	0.8	8
139	First Transfemoral Implantation of a Novel Transcatheter Valve in an LVAD Patient With Aortic Insufficiency. JACC: Case Reports, 2021, 3, 1806-1810.	0.3	8
140	Hemodynamics of concomitant tricuspid valve procedures at LVAD implantation. Journal of Cardiac Surgery, 2019, 34, 1511-1518.	0.3	7
141	Laparoscopic procedures in patients with cardiac ventricular assist devices. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 2181-2186.	1.3	7
142	Oral Milrinone for the Treatment of Chronic Severe Right Ventricular Failure in Left Ventricular Assist Device Patients. Circulation: Heart Failure, 2021, 14, e007286.	1.6	7
143	The Prevalence of Palliative Care Consultation in Deceased COVID-19 Patients and Its Association with End-of-Life Care. Journal of Palliative Medicine, 2021, , .	0.6	7
144	Outflow Graft Narrowing of the HeartMate 3 Left Ventricular Assist Device. Annals of Thoracic Surgery, 2023, 115, 1282-1288.	0.7	7

#	Article	IF	CITATIONS
145	The use of telemedicine in cardiogenetics clinical practice during the <scp>COVID</scp> â€19 pandemic. Molecular Genetics & Genomic Medicine, 2022, 10, e1946.	0.6	7
146	Hemodynamic Pump-Patient Interactions and Left Ventricular Assist Device Imaging. Cardiology Clinics, 2018, 36, 561-569.	0.9	6
147	Residual native left ventricular function optimization using quantitative 3D echocardiographic assessment of rotational mechanics in patients with left ventricular assist devices. Echocardiography, 2018, 35, 1606-1615.	0.3	6
148	High Transpulmonary Artery Gradient Obtained at the Time of Left Ventricular Assist Device Implantation Negatively Affects Survival After Cardiac Transplantation. Journal of Cardiac Failure, 2019, 25, 777-784.	0.7	6
149	Home Inotropes in Patients Supported with Left Ventricular Assist Devices. ASAIO Journal, 2019, 65, e7-e11.	0.9	6
150	HeartWare Ventricular Assist Device Cannula Position and Hemocompatibility-Related Adverse Events. Annals of Thoracic Surgery, 2020, 110, 911-917.	0.7	6
151	Fixed pulmonary hypertension and mechanical support: An unclear opportunity. Journal of Heart and Lung Transplantation, 2011, 30, 600.	0.3	5
152	Estimation of the Severity of Aortic Insufficiency by HVAD Flow Waveform. Annals of Thoracic Surgery, 2020, 109, 945-949.	0.7	5
153	CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced CardioOncology, 2020, 2, 515-518.	1.7	5
154	Cardiac transplantation in adult congenital heart disease with prior sternotomy. Clinical Transplantation, 2021, 35, e14229.	0.8	5
155	Impact of Venoarterial Extracorporeal Membrane Oxygenation Flow on Outcomes in Cardiogenic Shock. ASAIO Journal, 2021, Publish Ahead of Print, .	0.9	5
156	Twenty-four-hour blood pressure and heart rate variability are reduced in patients on left ventricular assist device support. Journal of Heart and Lung Transplantation, 2022, 41, 802-809.	0.3	5
157	Advances in mechanical circulatory support. Current Opinion in Cardiology, 2016, 31, 275-276.	0.8	4
158	Accepting Hearts From Hepatitis C–Positive Donor: Can We Expand the Donor Pool?. Journal of Cardiac Failure, 2017, 23, 762-764.	0.7	4
159	Echocardiographic evaluation of the effects of sacubitril–valsartan on vascular properties in heart failure patients. International Journal of Cardiovascular Imaging, 2020, 36, 271-278.	0.7	4
160	Omegaâ€3 and hemocompatibilityâ€related adverse events. Journal of Cardiac Surgery, 2020, 35, 405-412.	0.3	4
161	Hemocompatibility-related Adverse Events Following HeartMate II Left Ventricular Assist Device Implantation between Japan and United States. Medicina (Lithuania), 2020, 56, 126.	0.8	4
162	Optimal cannula positioning of HeartMate 3 left ventricular assist device. Artificial Organs, 2020, 44, e509-e519.	1.0	4

#	Article	IF	CITATIONS
163	Outcomes following left ventricular assist device exchange. Journal of Cardiac Surgery, 2020, 35, 591-597.	0.3	4
164	Presence of Intracardiac Thrombus at the Time of Left Ventricular Assist Device Implantation Is Associated With an Increased Risk of Stroke and Death. Journal of Cardiac Failure, 2021, 27, 1367-1373.	0.7	4
165	Cerebral vasoreactivity in HeartMate 3 patients. Journal of Heart and Lung Transplantation, 2021, 40, 786-793.	0.3	4
166	Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008968.	1.6	4
167	LVAD decommissioning: A percutaneous cardiac catheterization lab approach. Cardiovascular Revascularization Medicine, 2019, 20, 267-268.	0.3	3
168	Novel Formula to Calculate Three-Dimensional Angle Between Inflow Cannula and Device Body of HeartMate II LVAD. Annals of Thoracic Surgery, 2020, 109, 63-68.	0.7	3
169	Late inflow or outflow obstruction requiring surgical intervention after HeartMate 3 left ventricular assist device insertion. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 626-628.	0.5	3
170	Hypogammaglobulinemia following heart transplantation: Prevalence, predictors, and clinical importance. Clinical Transplantation, 2020, 34, e14087.	0.8	3
171	Should It Be Called "Suicide" or "Withdrawal of LVAD Support"?. Journal of Pain and Symptom Management, 2020, 60, e1-e3.	0.6	3
172	National outcomes of bridge to multiorgan cardiac transplantation using mechanical circulatory support. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 168-182.e11.	0.4	3
173	Discordance between lactic acidemia and hemodynamics in patients with advanced heart failure. Clinical Cardiology, 2021, 44, 636-645.	0.7	3
174	A principal components analysis of factors associated with successful implementation of an LVAD decision support tool. BMC Medical Informatics and Decision Making, 2021, 21, 106.	1.5	3
175	Consequences of functional mitral regurgitation and atrial fibrillation in patients with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2020, 39, 1398-1407.	0.3	3
176	Impact of socioeconomic deprivation on evaluation for heart transplantation at an urban academic medical center. Clinical Transplantation, 2022, 36, e14652.	0.8	3
177	Outcomes in Smaller Body Size Adults After HeartMate 3 Left Ventricular Assist Device Implantation. Annals of Thoracic Surgery, 2022, 114, 2262-2269.	0.7	3
178	Acute Myocarditis Secondary to Reactivated Chromosomally-Integrated Human Herpesvirus 6. Journal of Cardiac Failure, 2017, 23, 576-577.	0.7	2
179	Contemporary Perspectives in Durable Mechanical Circulatory Support: What Did We Learn in the Last 3ÂYears?. Current Cardiology Reports, 2018, 20, 6.	1.3	2
180	Heart transplantation in patients with localized prostate cancer—Are we denying a lifeâ€saving therapy due to an indolent tumor?. Clinical Transplantation, 2020, 34, e14080.	0.8	2

#	Article	IF	CITATIONS
181	Discordance between immunofluorescence and immunohistochemistry C4d staining and outcomes following heart transplantation. Clinical Transplantation, 2021, 35, e14242.	0.8	2
182	Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. American Heart Journal, 2021, 239, 11-18.	1.2	2
183	A Rare Case of Disseminated Tuberculosis and Hematological Malignancy in a Heart Transplant Recipient. Transplantation Proceedings, 2021, 53, 2626-2629.	0.3	2
184	The Role of Serial Right Heart Catheterization Survey in Patients Awaiting Heart Transplant on Ventricular Assist Device. ASAIO Journal, 2021, Publish Ahead of Print, .	0.9	2
185	OUP accepted manuscript. Interactive Cardiovascular and Thoracic Surgery, 2021, , .	0.5	2
186	PCI in Patients Supported With CF-LVADs: Indications, Safety, and Outcomes. Journal of Invasive Cardiology, 2016, 28, 238-42.	0.4	2
187	Fulminant Giant Cell Myocarditis Requiring Bridge With Mechanical Circulatory Support to HeartÂTransplantation. JACC: Case Reports, 2022, 4, 265-270.	0.3	2
188	Deep vein thrombosis and pulmonary embolism after heart transplantation. Clinical Transplantation, 2022, 36, e14705.	0.8	2
189	State of the Art Review: Evolution and Ongoing Challenges of Left Ventricular Assist Device Therapy. Structural Heart, 2018, 2, 262-273.	0.2	1
190	Outcomes of mechanical support for cardiogenic shock associated with late cardiac allograft failure. Journal of Cardiac Surgery, 2020, 35, 3381-3386.	0.3	1
191	Incidence and Clinical Significance of Hyperkalemia Following Heart Transplantation. Transplantation Proceedings, 2021, 53, 673-680.	0.3	1
192	Temporary surgical ventricular assist device for treatment of acute myocardial infarction and refractory cardiogenic shock in the percutaneous device era. Journal of Artificial Organs, 2021, 24, 199-206.	0.4	1
193	Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donorâ€specific antibody levels. Clinical Transplantation, 2021, , e14524.	0.8	1
194	Abstract 16747: The Artificial Pulse of the HeartMate3 LVAD Alters Mean Arterial Pressure Calculation, and the Relationship Between Arterial Pulse Pressure and Pulsatility Index. Circulation, 2020, 142, .	1.6	1
195	A Cold Taken to Heart. Circulation, 2015, 131, 1703-1711.	1.6	0
196	Troponin Assessment in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 125.	3.0	0
197	Response by Mehra et al to Letter Regarding Article, "Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure― Circulation, 2017, 136, 1872-1873.	1.6	0
198	HeartNetâ"¢ in an explanted heart of a Jehovah's Witness. Journal of Cardiac Surgery, 2018, 33, 765-765.	0.3	0

#	Article	IF	CITATIONS
199	Authors' Reply to the Comments of Joshua Fogel and Abhinav Saxena on Our Paper. Journal of Cardiac Failure, 2019, 25, 415.	0.7	0
200	Commentary: A pandemic blueprint for planning your act and acting your plan. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 137-138.	0.4	0
201	Abstract 17120: Association of Endotoxemia and Endothelin-1 With Development of Cardiac Allograft Vasculopathy After Heart Transplantation. Circulation, 2020, 142, .	1.6	0